New User:

Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 >>
06:55 EDTAAPL, TSM, SSNLFiPhone 6S with TSM processor has better battery life, 9to5Mac reports
Some models of Apple's (AAPL) new iPhone 6S ship with a processor made by TSMC (TSM), as opposed to a Samsung (SSNLF) made component, and the TSMC phones offer a better battery life than the Samsung models, 9to5Mac reports. Reference Link
06:54 EDTHTHTChina Lodging upgraded to Buy from Neutral at Goldman
Subscribe for More Information
06:52 EDTMSMorgan Stanley upgraded to Outperform from Market Perform at JMP Securities
JMP Securities upgraded Morgan Stanley to Outperform from Market Perform and established a $39 price target. Analsyt Devin Ryan upgraded shares based on valuation and said risk/reward has become more favorable.
06:51 EDTTRP, TLNTransCanada agrees to acquire Ironwood power plant from Talen Energy
TransCanada Corporation (TRP) announced that it has reached an agreement to acquire the Ironwood natural gas fired, combined cycle power plant in Lebanon, Pennsylvania, with a nameplate capacity of 778 MW, from Talen Energy (TLN) for $654M. At closing, $42M in debt will be assumed and then repaid within 45 days of closing out of funds placed into escrow by the seller. The acquisition is expected to be immediately accretive to earnings and cash flow and generate approximately $90M-$110M in earnings before interest, taxes, depreciation and amortization annually through a combination of capacity payments and energy sales.
06:50 EDTBEP, TLNBrookfield Renewable to acquire 292 MW hydroelectric portfolio from Talen Energy
Subscribe for More Information
06:50 EDTTLYSTilly's upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
06:49 EDTQLYSQualys upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse upgraded Qualys to Outperform and increased its price target to $45 from $35. Analyst Phillip Winslow said Qualys guided to a meaningful increase in the company's target operating model compared to past guidance and current expectations at its annual investor day. Winslow raised estimates meaningfully based on the company's new long-term expense plan, and as a result, upgraded shares.
06:48 EDTGWREGuidewire long-term outlook should be welcomed, says Deutsche Bank
Subscribe for More Information
06:48 EDTTSMTSMC reports September revenue down 13.8% to NT$64.51B
Subscribe for More Information
06:45 EDTMONMonsanto valuation attractive at current levels, says Deutsche Bank
Deutsche Bank analyst David Begleiter says the "robust" 2017 guidance and $3B accelerated share repurchase program offset Monsanto's Q4 miss and "weak" 2016 guidance. He views the stock as attractively valued at current levels and keeps a Buy rating on the name. Following the Q4 results, Begleiter cut his price target for shares to $104 from $110.
06:44 EDTTLN, TRPTalen Energy agrees to sell three PA power plants for $1.51B
Subscribe for More Information
06:43 EDTYUMYum! Brands upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
06:42 EDTECAEncana agrees to sell DJ Basin assets for $900M
Encana announced that its wholly-owned subsidiary, Encana Oil & Gas, has reached an agreement to sell its Denver Julesburg, or DJ, Basin assets in Colorado to a new entity 95% owned by Canada Pension Plan Investment board and 5% by The Broe Group. Total consideration to Encana under the transaction is approximately $900M. Encana will use the cash proceeds to further strengthen its balance sheet and create greater flexibility in this market environment. When combined with net proceeds from previously announced asset sales, cash proceeds from divestitures in 2015 will total approximately $2.7B. The company expects to have reduced its net debt in 2015 by approximately $3B by year-end.
06:40 EDTIMAXIMAX announces 15-theater agreement in China
Subscribe for More Information
06:39 EDTETREntergy agrees to sell RISEC to Carlyle Power Partners
Subscribe for More Information
06:37 EDTBSXBoston Scientific announces additional investment, right to acquire MValve
Boston Scientific announced that it has closed on an additional round of financing with MValve Technologies, a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS Valve, creating a unique mitral regurgitation treatment solution. Boston Scientific has provided the company with funding since 2012 and has an exclusive option to acquire MValve. MValve Technologies plans to utilize the new financing, in part, to fund a first-in-human clinical trial for the MValve docking system for transcatheter mitral valve replacement in patients with mitral regurgitation. The approach, in which the Boston Scientific Lotus Valve is deployed inside the MValve docking system, is designed to enable the treatment of mitral regurgitation in a broad range of patients, and to improve long-term clinical outcomes in this patient population. Both the dock and valve can be repositioned and recaptured, enabling precise valve placement and physician confidence prior to releasing. Mitral regurgitation is the most common type of heart valve disorder and occurs when the mitral valve does not close properly, causing an abnormal reversal of blood to flow from the left ventricle into the left atrium.
06:36 EDTDISH, VZ, T, TMUSDISH initiated with a Buy at Deutsche Bank
Subscribe for More Information
06:34 EDTNBIXNeurocrine reports positive results from Phase III Kinect 3 study of NBI-98854
Subscribe for More Information
06:33 EDTLUVSouthwest reports September passenger traffic up 9.3% to 11.54M
Southwest Airlines reported its September preliminary traffic statistics. The company flew 9.2B revenue passenger miles, or RPMs, in September, an 11.4% increase from the 8.3B RPMs flown in September 2014. Available seat miles, or ASMs, increased 8.4% to 11.1B in September 2015, compared with the September 2014 level of 10.3B. The September 2015 load factor was a record for the month of September at 82.7%, compared with 80.5% in September 2014.
06:32 EDTALXN, CELG, AMGN, GWPH, BLUE, FLKS, LBIO, OTIC, RXDX, BIIB, BMY, LLY, GILD, PFE, VRTX, BMRNPiper Jaffray explains why drug prices are justifiable
Piper Jaffray's team of Biopharma analysts, led by Joshua Schimmer, explain this morning in research note to investors why they believe drug prices are justifiable. The "fairly lopsided" drug-pricing discussion "noise" has created attractive entry points for stocks in the sector, the analysts argue. They say that after adjusting for actual inflation, the growth of drug prices "does not seem particularly concerning." The current dialogue on the topic under-emphasizes the need to provide "extremely attractive incentives" for companies to embark on the "highly risky, capital-intensive, long-development cycle drug development path which is needed to bring new cures for important diseases," the analysts contend. Schimmer's top picks are Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use